Data Integration and Platform Capabilities - The company has built the Tempus Platform, which includes over 700 unique data connections across more than 5,000 healthcare institution sites, enabling near real-time access to complex multimodal data[23]. - The platform's ability to contextualize test results and incorporate real-world evidence is expected to enhance decision-making for physicians regarding drug prescriptions and clinical trials[46]. - The platform is purpose-built to deploy AI across multiple disease areas, including oncology, neurology, and cardiology, aiming to transform healthcare through comprehensive data integration[35]. - The company has established new data pipelines to facilitate the free exchange of data between healthcare providers and diagnostic companies, addressing the issue of disconnected healthcare data[21]. - The company’s multimodal database is currently over 450 petabytes in size, with ongoing growth expected to drive innovations in patient treatment[62]. - The company has developed proprietary tools to facilitate data ingestion and has relationships with over 65% of all academic medical centers in the U.S.[56]. - The company aims to democratize the use of near-real-time molecular, clinical, and imaging data to improve therapeutic research and development[62]. Diagnostics and Testing Services - The Diagnostics product line provides Next Generation Sequencing (NGS) diagnostics and other testing services, with tests connected to clinical data, allowing for self-learning and improved accuracy[26]. - Intelligent Diagnostics are designed to provide personalized test results by incorporating a patient's longitudinal data and clinical context, improving the accuracy and relevance of laboratory tests[37]. - The Diagnostics product line offers a comprehensive suite of Intelligent Diagnostics, generating a steady stream of molecular data that fuels growth in the Data and applications product line[83]. - The company operates five laboratories providing NGS diagnostics, PCR profiling, and other tests, with a focus on cancer diagnostics, leveraging clinical data to enhance test accuracy[84]. - The Tempus xT test, launched in 2017, covers 648 genes and has received FDA approval in April 2023, demonstrating sensitivities greater than 98% for SNVs and 99.9% for MSI[88]. - The Tempus xR test, launched in 2023, provides full transcriptomic profiling and has shown that 43.4% of patients were matched to targeted therapies when combining DNA and RNA sequencing[89]. - The company has developed the tumor origin (TO) algorithm, which predicts the site of origin for cancer patients with unknown primary tumors, utilizing machine learning models trained on tumor RNA expression results from a de-identified multimodal database[74]. Business Model and Financial Performance - The company’s business model allows for monetization of de-identified data, creating network effects that enhance the value of its database and improve the precision of its tests[25]. - The company has a Remaining Total Contract Value (Remaining TCV) of more than $1.1 billion as of December 31, 2025, which includes approximately $300 million in potential future contractual opt-ins[103]. - Net Revenue Retention for the Insights product was approximately 126% for the year ended December 31, 2025, compared to the same cohort of customers for the period ended December 31, 2024[107]. - The average reimbursement for oncology NGS tests was approximately $1,600 in 2025, up from $1,450 in 2023, indicating a growth of about 10.3%[162]. - The company had received payment on approximately 55% of its clinical oncology NGS tests and 50% of hereditary tests from January 1, 2023, to December 31, 2024[162]. Clinical Trials and Research - The TIME Trial® program has signed more than 1,400 clinical trials into the network, identifying over 40,000 patients for potential enrollment as of December 31, 2025[116]. - The company has demonstrated that combining clinical and molecular data improved therapy matching, with 96% of patients matched to at least one clinical trial based on sequencing results and clinical data[90]. - Clinical oncology volume increased from approximately 31,000 samples sequenced in 2018 to approximately 367,500 samples in 2025, reflecting a significant growth in demand for sequencing services[95]. - The company has received approximately 6,500 tumor samples since 2017 for its Organoid lab, which supports drug screening applications across multiple cancer types[111]. Partnerships and Collaborations - The company entered into agreements with AstraZeneca and Pathos in April 2025 for the development of a foundation large multimodal model in oncology[171]. - AstraZeneca has committed to spend a minimum of $220 million on products and services under the Master Services Agreement (MSA) through December 31, 2026, with the potential to increase this commitment to $320 million by December 2028[176]. - Pathos will pay a total of $200 million in data license fees over three years, including an upfront payment of $50 million[173]. - Recursion Pharmaceuticals will pay an initial license fee of $22 million and an annual license fee totaling up to $160 million throughout the term of the agreement, which lasts until November 3, 2028[178]. - GSK has committed to spend a minimum of $180 million on products and services during the term of the GSK Agreement, with $70 million paid upon execution[177]. Regulatory Compliance and Quality Assurance - The company is subject to FDA regulations for its diagnostic products, which include requirements for product design, testing, and marketing[201]. - The company holds a current CLIA certificate for its laboratories, which must comply with standards for accurate and reliable testing[214]. - Laboratories performing high complexity testing must meet stringent requirements, including analytical validation for laboratory-developed tests (LDTs)[215]. - Non-compliance with CLIA and state regulations can lead to severe penalties, including license revocation and civil monetary penalties[217]. - The FDA has broad enforcement powers and can impose sanctions for non-compliance, including product recalls and operational restrictions[211]. Technology and Innovation - The company has developed proprietary software tools that allow for the abstraction of 50-100 discrete data elements per patient case in approximately one hour[191]. - The company has developed software applications like Hub and Lens to facilitate interaction with its Platform for healthcare providers and life sciences customers[70]. - The Hub application streamlines the ordering and tracking of laboratory tests, providing a comprehensive view of patient results over time[72]. - The Lens software application allows clinicians to filter a multimodal database to identify patient cohorts, facilitating data licensing opportunities without charge[76]. - The company aims to leverage AI and machine learning to identify care gaps in oncology and cardiology, enhancing patient outcomes[123]. - The company has integrated algorithmic diagnostics that utilize multimodal data to improve patient risk profiles and outcomes[125]. Sales and Market Strategy - The company employs approximately 205 sales representatives in the United States, primarily targeting oncologists and healthcare providers[141]. - The retention rate for physicians ordering more than 5 oncology NGS tests is 87% over a 12-month period[142]. - The company has approximately 30 sales executives in its Data and applications product line development organization as of December 31, 2025[149]. - The company aims to commercialize new clinical diagnostic algorithms through its existing provider network, leveraging its Diagnostics sales force[152]. - The company has a dedicated team focused on increasing the commercial adoption of its nP test for depression in the neuropsychiatry market[144]. Expansion and Growth - In February 2025, Tempus acquired Ambry Genetics Corporation, expanding its capabilities in hereditary cancer screening and entering new disease categories[58]. - The company’s acquisition of Ambry in February 2025 expanded its inherited risk screening capabilities for cancer and rare disease patients[87]. - The acquisition of Paige, Inc. in August 2025 enhances the company's capabilities in digital pathology, leveraging a dataset of nearly 7 million digitized pathology slide images[139]. - The company is focused on expanding its product offerings in cardiology, including algorithms for aortic stenosis and familial hypercholesterolemia[138]. - The company anticipates facing increasing competition from diagnostics companies and CROs as it expands its product offerings[156].

Financial Results - Tempus AI, Inc. reported preliminary financial results for Q4 and full year 2025 on January 11, 2026[6] - The total remaining contract value as of December 31, 2025, was disclosed in a press release on January 11, 2026[8] Corporate Communication - The company made an updated corporate presentation available on its investor relations website on January 11, 2026[9]

Core Viewpoint - Tempus AI achieved positive adjusted EBITDA for the first time in Q3 at $1.5 million, with Q4 revenue reaching $367 million, an 83% year-over-year increase. Despite beating revenue consensus, shares declined 22% since January due to widening net losses [1]. Financial Performance - Q4 revenue was pre-announced at $367 million, reflecting an 83% year-over-year growth, with diagnostics revenue at $266 million, up 121% year-over-year [1]. - Data and Applications segment contributed $100 million, a 25% increase, while the Insights segment grew by 68% [1]. - Total contract value exceeded $1.1 billion, and net revenue retention was 126%, indicating strong customer base expansion [1]. Profitability and Guidance - Q3 net loss widened to $80 million from $75.8 million a year earlier, despite higher revenue [1]. - Management guided for slightly positive adjusted EBITDA for the full year, absorbing integration costs from the Paige acquisition [1]. - 2026 guidance is crucial, with expectations for the foundation model to produce its first versions in Q1 2026 and ongoing MRD reimbursement progress [1]. Market Reaction and Stock Performance - Tempus shares have underperformed, down approximately 22% since the preliminary filing, despite strong revenue growth and achieving a key profitability milestone [1]. - Analyst consensus includes 7 Buy ratings and 7 Hold ratings, with an average price target of $86.71, suggesting potential upside if execution remains strong [1].

Core Insights - Tempus AI Inc. is a healthcare-focused AI company set to release its quarterly earnings on February 24, 2026, with an expected EPS of approximately -$0.04 and projected revenue of $362.6 million [1][6] Financial Performance - The company has a negative price-to-earnings (P/E) ratio of -49.16, yet its stock price has increased following an Outperform rating from Mizuho, which set a price target of $100 [2][6] - Tempus AI has a price-to-sales ratio of about 8.96, indicating investors are willing to pay nearly nine times the company's sales, while the enterprise value to sales ratio is approximately 9.58 [4] - The enterprise value to operating cash flow ratio is around -47.99, reflecting negative cash flow [4] - The company's debt-to-equity ratio is about 2.63, suggesting it has more than twice as much debt as equity, but it maintains a strong current ratio of approximately 3.28, indicating solid short-term financial stability [5] Product Development - Tempus AI announced a new HRD-RNA algorithm aimed at improving the detection of homologous recombination deficiency in tumors, which could enhance its market position [3][6]

Core Insights - A study by the American Cancer Society indicates that only about 20% of eligible individuals in the U.S. underwent lung cancer screening in 2024, suggesting a significant opportunity to improve early detection and potentially prevent approximately 62,110 lung cancer deaths over five years [1] Company Developments - Tempus AI, Inc. has partnered with Median Technologies to integrate the eyonis LCS solution into the Tempus Pixel platform, enhancing lung cancer screening capabilities with AI-based software [2] - The company received FDA 510(k) clearance for its Tempus ECG-Low EF software, which identifies patients with low left ventricular ejection fraction [3] - Tempus strengthened its imaging capabilities through the acquisition of Arterys in 2022, integrating AI-driven imaging tools into its ecosystem [4] Peer Updates - GE HealthCare launched the Voluson Performance series and acquired icometrix to enhance its AI-powered brain imaging analysis capabilities [5] - NANO-X IMAGING LTD received CE mark certification for its Nanox.ARC system, which generates tomographic images from a single sweep [6] Stock Performance - Tempus' shares have declined by 14.3% over the past year, while the industry has seen a 33.6% decline, contrasting with a 17.7% increase in the S&P 500 [7] - The company currently trades at a forward 12-month Price-to-Sales (P/S) ratio of 6.45X, above the industry average of 5.66X [11] Earnings Estimates - Tempus AI's loss per share estimate for 2025 has remained unchanged over the past 30 days, with current estimates at -$0.59 for the current year and -$0.21 for the next year [12][13]

Core Insights - AppLovin shares surged 11.2% last week, driven by Bank of America's defense of the stock after a post-earnings sell-off [1] - Tempus AI also saw an 11% increase, attributed to a preliminary Q4 report showing an 83% year-over-year revenue growth [1] - Micron Technology gained 4.01% as Bank of America raised its price target due to increasing AI memory demand [1] AppLovin - AppLovin's stock price increased significantly after Morgan Stanley raised its price target to $800, maintaining an Overweight rating [1] - The company reported Q4 2025 revenue of $1.66 billion, a 66% increase year-over-year, with an adjusted EBITDA margin of 84% [1] - Despite the recent gains, AppLovin is still down approximately 38% year-to-date from January highs, leading to discussions about its valuation among investors [1] Tempus AI - Tempus AI's stock rose following a preliminary Q4 2025 report indicating revenue of $367 million, an 83% increase year-over-year, and a record total contract value exceeding $1.1 billion [1] - The diagnostics segment experienced a remarkable growth of 121% year-over-year [1] - CEO Eric Lefkofsky expressed confidence in the company's strong position entering 2026, with a net revenue retention rate of 126% [1] Micron Technology - Micron's stock price increased after Bank of America raised its price target, citing accelerating demand for high-bandwidth memory in AI infrastructure [1] - The company reported cloud memory revenue of $5.28 billion in fiscal Q1 2026, nearly doubling year-over-year, with a gross margin of 66% [1] - Micron is recognized as one of the few companies capable of supplying high-bandwidth memory at scale, with 37 out of 43 analysts rating the stock as a buy or strong buy [1] AI Sector Overview - The VanEck Semiconductor ETF rose 1.8%, indicating a positive trend in the AI sector, particularly in semiconductors [1] - Software stocks are struggling, while segments like memory and networking are experiencing strong gains [1] - The broader AI market is characterized by significant divergence, with semiconductors leading the performance [1]

Core Insights - Artificial intelligence, particularly generative AI, is significantly transforming the MedTech industry, with companies like Tempus AI, Inc. leading the way in AI-driven healthcare solutions [1] Product Developments - Tempus launched its HRD-RNA algorithm in February 2026, a next-generation AI model designed to identify patients likely to respond to platinum-based chemotherapy or PARP inhibitors [2] - In January 2026, Tempus introduced Paige Predict, an AI-powered digital pathology application that analyzes whole slide images to assist in testing decisions [3] - Tempus received FDA clearance in July 2025 for its ECG-Low EF software, which uses AI to identify patients with low left ventricular ejection fraction [3] - The company also launched Notetaker in May 2025, an AI clinical assistant that records patient sessions to generate clinical notes for electronic health records [3] Industry Collaborations - GE HealthCare is collaborating with NVIDIA to utilize AI and high-performance computing to enhance patient comfort and reduce radiologist burnout [4] - Stryker's Mako SmartRobotics platform integrates AI to improve surgical accuracy in knee and hip procedures, with significant adoption and a recurring revenue model [5] Financial Performance - Tempus' stock has decreased by 21.9% over the past year, while the industry has seen a decline of 37.8%, contrasting with a 14.8% increase in the S&P 500 [6] - The company's current forward Price-to-Sales ratio is 6.63X, higher than the industry average of 5.66X, indicating an expensive valuation [9] Earnings Estimates - Tempus' loss per share estimates for 2025 have remained stable over the past 30 days, with projections of -0.59 for the current year and -0.21 for the next year [10][11]

Core Insights - The article discusses the investment strategy of Duan Yongping, highlighting significant changes in his portfolio as of the end of 2025, with a total market value of approximately $17.489 billion, equivalent to over 120 billion RMB [2]. Group 1: Portfolio Adjustments - Duan Yongping significantly reduced his position in Apple, which was previously his largest holding, with a decrease of 7.09% in shares held [4]. - He increased his stake in Nvidia by over 1,110.62%, raising his holdings to 7,237,100 shares valued at approximately $1.35 billion [4]. - Duan also added to his positions in Google and Pinduoduo, while drastically cutting his investment in ASML by 87.63% [3][4]. Group 2: New Investments - Duan initiated small positions in three AI-focused companies: CoreWeave, Credo Technology, and Tempus AI, with respective portfolio allocations of 0.12%, 0.12%, and 0.04% [2][4]. - The portfolio reflects a strategic shift towards technology and AI sectors, indicating a focus on emerging trends in the market [2].

Core Insights - Tempus AI (TEM) shares increased following the launch of a new AI algorithm for identifying cancer patients responsive to platinum-based chemotherapy, with preliminary Q4 revenue reported at $367 million, an 83% year-over-year increase, and total contract value exceeding $1.1 billion [1] Group 1: Company Developments - Tempus AI introduced the Pan-Cancer HRD-RNA algorithm, which utilizes RNA analysis to identify Homologous Recombination Deficiency, offering a real-time view of tumor biology [1] - The algorithm has shown that patients with HRD-RNA positive metastatic pancreatic cancer have significantly lower mortality risk compared to those receiving non-platinum therapies [1] - The algorithm is currently available for research purposes, with clinical availability anticipated later in 2026 [1] Group 2: Financial Performance - Preliminary Q4 revenue for Tempus was reported at $367 million, marking an 83% increase year-over-year [1] - The total contract value for Tempus exceeded $1.1 billion, indicating strong demand for its services [1] Group 3: Market Sentiment - Analysts have set a consensus target price of $85.69 for Tempus, suggesting nearly 50% upside from current trading levels [1] - The stock has received 2 Strong Buy and 5 Buy ratings, reflecting confidence in Tempus's revenue growth and expanding AI-driven diagnostics platform [1] - Despite recent volatility, the stock remains down 18.54% over the past month, indicating potential market concerns ahead of the earnings report [1]

Core Insights - Tempus AI, Inc. has launched a new AI-powered cancer diagnostic algorithm, the Pan-Cancer HRD-RNA algorithm, which utilizes RNA analysis to identify Homologous Recombination Deficiency, enhancing the identification of patients likely to respond to specific chemotherapy treatments [3][9] - The company's stock has seen a 6.86% increase over the past week, currently trading at $57.29, although it remains down 18.54% over the past month [2][6] - Preliminary Q4 results indicate a revenue of $367 million, representing an 83% year-over-year increase, with a total contract value exceeding $1.1 billion [4][9] - Analysts maintain a bullish outlook with a consensus target price of $85.69, suggesting nearly 50% upside potential from current stock levels [5][9] Company Developments - The HRD-RNA algorithm is currently available for research use, with clinical availability anticipated later in 2026, indicating ongoing innovation within the company's AI-driven diagnostics platform [3][6] - Key items to monitor in the upcoming earnings report include detailed financials, commentary on the path to profitability, and guidance for 2026 [4] Market Sentiment - Wall Street analysts have issued 2 Strong Buy and 5 Buy ratings for Tempus, reflecting confidence in the company's accelerating revenue growth and expanding diagnostic capabilities [5]